Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
108.95
+0.25 (0.23%)
At close: May 12, 2025, 4:00 PM
110.01
+1.06 (0.97%)
After-hours: May 12, 2025, 7:32 PM EDT
Novartis AG Market Cap
Novartis AG has a market cap or net worth of $213.30 billion as of May 12, 2025. Its market cap has increased by 6.29% in one year.
Market Cap
213.30B
Enterprise Value
238.71B
1-Year Change
6.29%
Ranking
Category
Stock Price
$108.95
Market Cap Chart
Since April 11, 2001, Novartis AG's market cap has increased from $116.62B to $213.30B, an increase of 82.90%. That is a compound annual growth rate of 2.54%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
May 9, 2025 | 212.98B | 9.47% |
Dec 31, 2024 | 194.55B | -6.26% |
Dec 29, 2023 | 207.54B | 5.57% |
Dec 30, 2022 | 196.59B | 0.47% |
Dec 31, 2021 | 195.68B | -9.46% |
Dec 31, 2020 | 216.12B | -1.25% |
Dec 31, 2019 | 218.84B | 10.05% |
Dec 31, 2018 | 198.86B | -0.23% |
Dec 29, 2017 | 199.33B | 15.27% |
Dec 30, 2016 | 172.91B | -16.21% |
Dec 31, 2015 | 206.38B | -8.20% |
Dec 31, 2014 | 224.80B | 15.54% |
Dec 31, 2013 | 194.57B | 27.72% |
Dec 31, 2012 | 152.34B | 16.39% |
Dec 30, 2011 | 130.89B | -2.38% |
Dec 31, 2010 | 134.07B | 8.76% |
Dec 31, 2009 | 123.28B | 9.40% |
Dec 31, 2008 | 112.68B | -11.65% |
Dec 31, 2007 | 127.53B | -4.95% |
Dec 29, 2006 | 134.18B | 5.35% |
Dec 30, 2005 | 127.36B | 2.12% |
Dec 31, 2004 | 124.72B | 9.81% |
Dec 31, 2003 | 113.58B | 7.17% |
Dec 31, 2002 | 105.97B | 0.63% |
Dec 31, 2001 | 105.31B | -9.70% |
View and export this data all the way back to 2001.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
Eli Lilly and Company | 676.67B |
Johnson & Johnson | 370.82B |
UnitedHealth Group | 343.81B |
AbbVie | 337.63B |
Novo Nordisk | 292.03B |
Abbott Laboratories | 229.26B |
AstraZeneca | 210.42B |
Merck & Co. | 202.75B |